Biotechnology

Friday Dec 11, 2020 - 2:35 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening…

Thursday Dec 10, 2020 - 10:42 am

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176.…

Thursday Dec 10, 2020 - 9:49 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate…

Wednesday Dec 09, 2020 - 1:41 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote…

Tuesday Dec 08, 2020 - 2:16 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has…

Tuesday Dec 08, 2020 - 1:59 pm

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens,…

Monday Dec 07, 2020 - 10:10 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Upcoming Investor Webcast

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological crop protection for high value crops, today announced an upcoming live webcast for its investment community. According to the update, MustGrow is poised to capitalize in 2021 and beyond in a rapidly growing market as regulatory framework moves to favor organic biopesticides and bioherbicides. The webcast is scheduled to…

Thursday Dec 03, 2020 - 3:25 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate in the LD Micro Virtual Main Event 2020 Conference. According to the update, 180 Life Sciences CEO Dr. James Woody is scheduled to present at…

Wednesday Dec 02, 2020 - 11:16 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Files Patent Application for Flexible EEG Cap

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) entitled, “FULL HEAD APPARATUS AND ELECTRODES FOR CONDUCTING ELECTROENCEPHALOGRAPHY.” “The new EEG product for which Brain Scientific is seeking a patent approval is a flexible head cap for conducting electroencephalography,” said BRSF Marketing Director Irina Nazarova. “The cap carries…

Tuesday Dec 01, 2020 - 1:19 pm

InvestorNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Test Results for Control of Threat to $25 Billion Banana Industry

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has announced initial test results of its mustard-derived organic biopesticide formulation designed to control Fusarium wilt TR4, a destructive pathogen threatening the global banana industry, which is valued at $25 billion. Completed via third-party independent laboratory CyberAgrot SAS in Colombia, the testing reported 100% control Fusarium wilt TR4, known as Panama disease. The disease led to the declaration of…

Monday Nov 30, 2020 - 3:25 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Agreement for Expansion into EU Market

Brain Scientific’s (OTCQB: BRSF) Vice President of Marketing, Stuart Bernstein, has written an article for Health Care Business News titled, “COVID's influence on neurology drives need for disposable technologies.” The piece discusses increased concern for health care and frontline workers treating emergent cases for COVID-19 patients developing neurological symptoms and conditions, as well as a critical need for testing solutions. The article reads, “Sudden onset…

Monday Nov 30, 2020 - 11:00 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”), for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients…

Wednesday Nov 25, 2020 - 3:14 pm

InvestorNewsBreaks – Why Brain Scientific Inc. (BRSF) Is ‘One to Watch’

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. The company’s mission is to modernize brain diagnostics by employing leading-edge technologies to bridge the widening gap in access to quality care. A recent article discussing the company reads, “Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade,…

Wednesday Nov 25, 2020 - 2:44 pm

InvestorNewsBreaks – Trxade Group Inc.’s (NASDAQ: MEDS) Platform Meets Today’s Demands Through Intelligent Design

Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health care platform, is ideally situated as the global pandemic has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services. Trxade Group’s business model appears to aptly and effectively meet today’s demands, largely demonstrated by the company’s revenue growth that has far exceeded…

Wednesday Nov 25, 2020 - 12:28 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, will be providing its digital therapeutics solution to qualified employees of a U.S.-based Fortune 500 technology company. The contract, which goes into effect on Jan. 1, 2021, with the beginning of a new benefits year, calls for Dario to provide its digital diabetes tools and coaching to employees and their dependents. “We believe that…

Tuesday Nov 24, 2020 - 3:18 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that, in celebration of its recently completed initial public offering, it will ring the Nasdaq Stock Exchange opening bell on November 27, 2020. 180 Life Sciences CEO Dr. James…

Tuesday Nov 24, 2020 - 2:46 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Korea Biomedical Review Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a recent article published in the Korea Biomedical Review. The piece, titled “Yuhan emerges as global new-drug developer with $3.6 billion tech export,” discusses Yuhan Corp.’s (OCT: YUHNF) move to enter technology transfer deals with global pharmaceutical…

Tuesday Nov 24, 2020 - 1:50 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how…

Tuesday Nov 24, 2020 - 1:23 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast, CNS Pharmaceuticals CEO John Climaco explains that the company has recently submitted an investigational new drug (“IND) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer…

Tuesday Nov 24, 2020 - 1:01 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on Dec. 1, 2020. According to the update, Genprex’s executive vice president and COO, Michael Redman, will virtually deliver a company overview to investors followed by a guided question…

Tuesday Nov 24, 2020 - 10:45 am

InvestorNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Outlines Investor Initiatives, Announces Conference Presentation

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, announced its upcoming investor awareness initiatives today. In addition, the company will be conducting a presentation today at the Future of Food Investment Conference; one-on-one investor meetings are also being scheduled for next week. According to the announcement, MustGrow’s key programs and…

Monday Nov 23, 2020 - 12:37 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures Additional Patents, Significantly Strengthening IP Portfolio

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice from the USPTO that it will publish application 62/722,263 “Method…

Friday Nov 20, 2020 - 11:03 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Simply Wall St Article

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in a recent Simply Wall St article. The piece, titled “Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?,” explores the rate of the company’s annual negative free cash flow (“cash burn”) and whether it should be concerning to shareholders. The article reads, “Even…

Thursday Nov 19, 2020 - 11:53 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Presents Promising Dario DTx Study Results

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (“DTS”). According to the update, the results showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario's…

Tuesday Nov 17, 2020 - 1:25 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Agreement for Expansion into EU Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into an agreement with Europe’s leading certification and compliance company AFINA s.r.o. Under the agreement, AFINA will act as an authorized representative for Brain Scientific in the European Union (“EU”) and assist with registering Brain Scientific’s advanced EEG solutions in 32 countries in the European market. “We believe our next generation rapid…

Tuesday Nov 17, 2020 - 12:48 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Requests Protocol Amendment to Phase 2b Study to Add Study Arm

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be submitting a protocol amendment request to the U.S. Food and Drug Administration (“FDA”) for its Phase 2b OPTION 2 trial of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The proposed amendment requests the potential to add a study arm that uses an immediate-release MS1819…

Tuesday Nov 17, 2020 - 12:18 pm

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY product…

Monday Nov 16, 2020 - 2:19 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation Schedule for Upcoming Investor Conferences

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will participate in two upcoming investor conferences. According to the update, Processa will participate in one-on-one meetings at the Craig-Hallum Alpha Select Virtual Conference on Tuesday, Nov. 17, 2020, and the Benchmark Annual Discovery 1x1 Investor…

Monday Nov 16, 2020 - 10:49 am

InvestorNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Annual General Shareholder’s Meeting Results, Secures Order for MiQLab(TM) System

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced the voting results of the company’s 2020 Annual General Shareholder’s Meeting held on November 10, 2020 in Vancouver, British Columbia. According to the update, a total of 48,273,080 common shares were voted at the meeting, representing 42.26% of the votes attached to all outstanding…

Friday Nov 13, 2020 - 11:29 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q3 2020 Results, Provides Corporate Update

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a business update via conference call, for which the replay may…

Friday Nov 13, 2020 - 10:31 am

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided an update on its CNS pipeline and business progress. “We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to…

Thursday Nov 12, 2020 - 1:15 pm

InvestorNewsBreaks – CB Scientific Inc. (CBSC) Enters Definitive Agreement to Acquire Datrix LLC

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced definitive purchase agreement to acquire Datrix LLC, a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. The…

Wednesday Nov 11, 2020 - 11:21 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its senior vice president of intellectual property and licensing, Thomas Gallagher, will participate at the annual NYC-based Life Sciences Summit. Gallagher will take part in a panel discussion titled, “Show Me the Money: Preparing Your Company for Funding,” at the event, slated to…

Tuesday Nov 10, 2020 - 2:40 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Completion of Strategic Merger

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. Prior to the merger’s closing, KBL Merger Corp. changed its name to 180 Life Sciences Corp., and 180 Life Sciences Corp. changed its name to…

Tuesday Nov 10, 2020 - 1:10 pm

InvestorNewsBreaks – Antibe Therapeutics Inc. (TSXV: ATE) (OTCQB: ATBPF) Graduates to the TSX

Antibe Therapeutics (TSXV: ATE) (OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced its receipt of final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX. According to the update, Antibe’s shares will commence TSX trading under the company’s existing ticker symbol “ATE” at market open…

Tuesday Nov 10, 2020 - 11:35 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According to the update, Dr. Gittes is the inventor of GNPX’s licensed diabetes gene therapy technology that is currently in development and serves as the chief of pediatric surgery and surgeon-in-chief…

Tuesday Nov 10, 2020 - 11:12 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. Under the agreement, Asymchem will implement fermentation, verify protein expression and ultimately…

Tuesday Nov 10, 2020 - 10:41 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Selected to Present at Upcoming Investor Conferences

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is slated to present at two upcoming investor conferences. Representing LexaGene at the conferences will be founder and CEO Jack Regan. Regan will be a presenter at the Investor Summit Group Conference held Nov. 18, 2020, at 1:30 p.m. and at the Canaccord Genuity 2020 Medical Technologies &…

Monday Nov 09, 2020 - 9:45 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin. CNSP’s lead drug candidate – Berubicin –…

Friday Nov 06, 2020 - 9:17 am

InvestorNewsBreaks – Turning Point Therapeutics Inc. (NASDAQ: TPTX) Secures $460M in Underwritten Public Offering

Turning Point Therapeutics (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, has closed an underwritten public offering of 5,287,357 shares of its common stock, including 689,655 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Turning Point Therapeutics secured approximately $460 million in gross proceeds, with each of the…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions